Zobrazeno 1 - 10
of 162
pro vyhledávání: '"MT Alonso"'
Autor:
P Pacheco, MÁ Carvajal, J Ibañez, MT Alonso, M Tobaruela, L Fructuoso, P Torrano, JA Gutierrez, M Hernández
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe2808a655c4cb661a25418352b70e55
https://doi.org/10.1136/ejhpharm-2022-eahp.324
https://doi.org/10.1136/ejhpharm-2022-eahp.324
Autor:
M Soria-Soto, Najera-Perez, C Fernández-Zamora, MA Page-Del Pozo, MA Meroño-Saura, N de Bejar-Riquelme, M Pascual-Barrriga, A Gomez-Gil, MT Alonso-Dominguez, T Rodriguez-Martinez
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Non-valvular atrial fibrillation (NVAF) is the most common cardiac arrhythmia in clinical practice. In Spain, the stipulated recommendations to select anticoagulants are: use of direct oral anticoagulants (DOAC) in the case of poor INR con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d09a06f4526e7553d3f3672437a88abb
https://doi.org/10.1136/ejhpharm-2019-eahpconf.372
https://doi.org/10.1136/ejhpharm-2019-eahpconf.372
Autor:
V Dominguez Leñero, J. León Villar, GG Alberto, MA Meroño Saura, N De Bejar Riquelme, B Arribas Díaz, SS Manuel, MT Alonso Dominguez, A Agámez Luengas, JC Titos Arcos, C Fernández Zamora
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: According to several neoadjuvant studies, pertuzumab combined with chemotherapy based on trastuzumab is effective in early and advanced HER2-positive breast cancer (BC). Based on the highest rate (51.9%) of complete pathological responses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7595c90bb5bf3b56e89140007d7103b7
https://europepmc.org/articles/PMC7535199/
https://europepmc.org/articles/PMC7535199/
Autor:
I Sánchez-Martinez, M Soria-Soto, I Gorostiza-Frias, MT Alonso-Dominguez, P Selvi-Sabater, N Manresa-Ramón, AM Rizo-Cerdá, J Leon-Villar, Najera-Perez, N Bejar-Riquelme
Publikováno v:
European Journal of Hospital Pharmacy. 23:A69.2-A70
Background With the advent of new treatments for hepatitis C, we have achieved high cure rates, although this entails a significant increase in drug spending. Purpose To describe and analyse spending on HCV treatment in 2015. Material and methods Dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c2e4aa072225d6ee751492cc1c3db41f
https://doi.org/10.1136/ejhpharm-2016-000875.157
https://doi.org/10.1136/ejhpharm-2016-000875.157
Autor:
Juana Mulero, Mdc Sánchez-Mulero, M Losada, I De Gorostiza-Frías, MT Alonso-Dominguez, N Manresa-Ramón, AM Rizo-Cerdá, I Sánchez-Martinez, Pilar Zafrilla, P Selvi-Sabater
Publikováno v:
European Journal of Hospital Pharmacy. 23:A189.2-A190
Background Many authors have hypothesised that oxidative stress and exudative age related macular degeneration (AMD) share common antecedents and proposed that novel biomarkers associated with oxidative stress should be evaluated for their potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2d46e3a8c64a0408d9f9e0819e47c08
https://doi.org/10.1136/ejhpharm-2016-000875.428
https://doi.org/10.1136/ejhpharm-2016-000875.428
Autor:
MT Alonso-Dominguez, AM Rizo-Cerdá, B Arribas-Díaz, N De-Béjar-Riquelme, A Gomez-Gil, MC Sanchez-Mulero, M Soria-Soto, M Ventura-Lopez, P Selvi-Sabater, I De-Gorostiza-Frías
Publikováno v:
European Journal of Hospital Pharmacy. 23:A166.2-A167
Background Manual replacement of drugs in semi-automatic storage and dispensing systems takes long time for the pharmacy auxiliary staff, particularly for drugs that need some manipulation before their replacement. Purpose To achieve a reduction in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee769b0543a81a65eb021c120f2804cc
https://doi.org/10.1136/ejhpharm-2016-000875.375
https://doi.org/10.1136/ejhpharm-2016-000875.375
Autor:
S Fernandez-Cañabate, B Arribas-Díaz, MC Sanchez-Mulero, P Selvi-Sabater, I De Gorostiza-Frías, MT Alonso-Dominguez, N Manresa-Ramón, AM Rizo-Cerdá, I Sánchez-Martinez, M Ventura-Lopez
Publikováno v:
European Journal of Hospital Pharmacy. 22:A199.2-A200
Background Some patients directly hospitalised via the emergency department are changed from their current home treatment. The pharmacy department aims to identify any errors and rectify them. Purpose To find out how many home treatment prescriptions
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae25f58f75ff64a21097f1c525be22bf
https://doi.org/10.1136/ejhpharm-2015-000639.480
https://doi.org/10.1136/ejhpharm-2015-000639.480
Autor:
I Sánchez-Martinez, MC Sanchez-Mulero, MT Alonso-Dominguez, P Selvi-Sabater, M Soria-Soto, B Arribas-Díaz, N De Bejar Riquelme, N Manresa-Ramón, AM Rizo-Cerdá, I De Gorostiza-Frías
Publikováno v:
European Journal of Hospital Pharmacy. 22:A164.2-A164
Background Ondansetron is a powerful and highly selective serotonin receptor antagonist used to prevent nauseas and vomiting after surgery or chemotherapy. Sialadenitis consists in the formation of stones along the salivary duct. Purpose To describe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38ff73ddf9f0595b6cbccdf0dc0d57b6
https://doi.org/10.1136/ejhpharm-2015-000639.395
https://doi.org/10.1136/ejhpharm-2015-000639.395
Autor:
P Selvi-Sabater, MM Sanchez-Catalicio, I Sánchez-Martinez, B Arribas-Díaz, I Gorostiza-Frias, MT Alonso-Dominguez, JC Titos-Arcos, N Manresa-Ramón, AM Rizo-Cerdá, A Espuny-Miró
Publikováno v:
European Journal of Hospital Pharmacy. 21:A108.2-A108
Background Telaprevir is one of the new drugs for chronic hepatitis C genotype 1. As it is a new drug is necessary to be aware of the emergence of new adverse reactions that may not be included in the SPC. Purpose To investigate possible severe adver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2dbb87a5cdedc789daa28a4eda4ebac2
https://doi.org/10.1136/ejhpharm-2013-000436.266
https://doi.org/10.1136/ejhpharm-2013-000436.266
Autor:
N Gorostiza-Frias, MT Alonso-Dominguez, P Selvi-Sabater, JC Titos-Arcos, I Sanchez-Quiles, I Sánchez-Martinez, N Manresa-Ramón, AM Rizo-Cerdá, B Arribas-Díaz, MM Sanchez-Catalicio
Publikováno v:
European Journal of Hospital Pharmacy. 21:A54.2-A54
Background Eribulin is a new drug against metastatic breast cancer, one of the most common cancers in women Purpose To study the effectiveness and safety of treatment with eribulin in metastatic breast cancer in patients who have been treated with at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c601ab2f7a57dc2984377c7f0936eb8a
https://doi.org/10.1136/ejhpharm-2013-000436.132
https://doi.org/10.1136/ejhpharm-2013-000436.132